ArticleFrontiers in oncology2025
Case Report: First case of low-grade myofibroblastic sarcoma of the vulva during pregnancy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Full-term delivery in pregnancy complicated with suspected residual cervical alveolar soft part sarcoma: a case report and literature review.BMC pregnancy and childbirth · 2026Review
- Synchronous low-grade myofibroblastic sarcoma and small cell lung cancer in a patient with situs inversus totalis: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-grade myofibroblastic sarcoma (LGMFS) of the vulva is exceptionally rare, with only two prior cases reported. We present the third documented case globally and the first occurring during pregnancy, highlighting diagnostic and therapeutic challenges in this unique clinical scenario. A 34-year-old woman presented with a recurrent vulvar mass initially misdiagnosed as angiomyofibroblastoma. The lesion reappeared asymptomatically during pregnancy and was conservatively managed with ultrasound surveillance, followed by term cesarean delivery to mitigate perineal trauma risks. Postpartum evaluation revealed a 3.7 cm T2-hyperintense nodule on MRI. Although intraoperative frozen sections suggested benign margins, definitive histopathology and molecular studies (CD34+/SMA+; FISH-negative for COL1A1::PDGFB fusion and MDM2 amplification) confirmed LGMFS. Radical vulvectomy with 2 cm margins achieved disease-free survival at 17 months without adjuvant therapies. This case underscores that LGMFS may recur silently during pregnancy, necessitating rigorous histopathological re-evaluation of prior benign diagnoses. Multidisciplinary coordination enabled safe deferral of definitive surgery until postpartum without compromising outcomes, while radical excision alone proved curative, reflecting the tumor's indolent biology. Our findings establish the first pragmatic framework for managing vulvar LGMFS in pregnancy, emphasizing tailored surgical planning over routine adjuvant interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.